Unlock Large Customers’ Doors With Key Account Management

Posted by Bill Coyle on Mon, Feb 02, 2015

As key account management (KAM) becomes more prevalent for pharmaceutical companies trying to court large clients, how are they actually implementing it? And what challenges are they facing as they try to do so?


>
Read More

Direct-to-Patient Models in Pharma—A Harbinger of Things to Come?

Posted by Bill Coyle on Thu, Jun 12, 2014

Over the past few years, pharmaceutical companies have started implementing direct-to-patient models to directly sell and distribute prescription pharmaceutical products.  What does that mean to the patient? No more waiting in line at the pharmacy, but instead, going to a brand.com website, entering information, paying a co-pay or the full amount, and then receiving the drug in the mail a few days later.


>
Read More

Blockbuster Drug Boycott? What ESI’s Sovaldi Threat Means to Big Pharma

Posted by Bill Coyle on Wed, Apr 23, 2014

Pharmacy benefit manager Express Scripts (ESI) recently threatened to form a coalition of customers and network members that would drop coverage of Gilead’s much-heralded, yet costly hepatitis C drug Sovaldi once viable competition arises. ESI’s announcement sparked conversations throughout the U.S. pharma industry, especially among companies coming to market with specialty drugs in the next one to two years, namely:


>
Read More